US EditionPublished • loading... • Updated
Study Finds GLP-1 Drug Might Help Curb Obsessive Food Cravings
Eli Lilly's orforglipron pill helped patients lose nearly 10% body weight and lower blood sugar in trials, offering a convenient alternative to injectable drugs.
- Eli Lilly plans to roll out a daily GLP-1 pill, orforglipron, for people with obesity and type 2 diabetes.
- A randomized trial enrolled 1,600 participants from 10 countries and split them into four groups: low, medium, high dose, and placebo, with lifestyle advice given to all participants; earlier trials showed orforglipron caused weight loss but at smaller percentages than injectable GLP-1s.
- Trial results show dose-dependent weight loss, with the high-dose group losing almost 10 percent of body weight and blood sugar by nearly 2 percent, while medium and low-dose groups lost 7 percent and 5 percent respectively, and the placebo group lost less than three percent.
- Deborah Horn said a pill is more convenient and, because it needn't be refrigerated or use syringes, should be cheaper to make and deliver.
- Given the consistent efficacy gap with injectables, trials show orforglipron enables weight loss for both conditions at smaller percentages than injectable semaglutide drugs, while GLP-1 mechanisms remain unclear, needing further research.
Insights by Ground AI
67 Articles
67 Articles
Coverage Details
Total News Sources67
Leaning Left8Leaning Right14Center11Last UpdatedBias Distribution43% Right
Bias Distribution
- 43% of the sources lean Right
43% Right
L 24%
C 33%
R 43%
Factuality
To view factuality data please Upgrade to Premium
